iScience (Oct 2022)

Cystatin C is associated with adverse COVID-19 outcomes in diverse populations

  • Sam O. Kleeman,
  • Mattia Cordioli,
  • Paul R.H. J. Timmers,
  • Atlas Khan,
  • Pinkus Tober-Lau,
  • Florian Kurth,
  • Vadim Demichev,
  • Hannah V. Meyer,
  • James F. Wilson,
  • Markus Ralser,
  • Krzysztof Kiryluk,
  • Andrea Ganna,
  • Kenneth Baillie,
  • Tobias Janowitz

Journal volume & issue
Vol. 25, no. 10
p. 105040

Abstract

Read online

Summary: COVID-19 has highly variable clinical courses. The search for prognostic host factors for COVID-19 outcome is a priority. We performed logistic regression for ICU admission against a polygenic score (PGS) for Cystatin C (CyC) production in patients with COVID-19. We analyzed the predictive value of longitudinal plasma CyC levels in an independent cohort of patients hospitalized with COVID-19. In four cohorts spanning European and African ancestry populations, we identified a significant association between CyC-production PGS and odds of critical illness (n cases=2,319), with the strongest association captured in the UKB cohort (OR 2.13, 95% CI 1.58-2.87, p=7.12e-7). Plasma proteomics from an independent cohort of hospitalized COVID-19 patients (n cases = 131) demonstrated that CyC production was associated with COVID-specific mortality (p=0.0007). Our findings suggest that CyC may be useful for stratification of patients and it has functional role in the host response to COVID-19.

Keywords